Skip to main content

Loading market data...

CORT

Corcept Therapeutics Incorporated

NASDAQ • United states

$116.45

+$4.35

(+3.88%)

Source: Yahoo Finance · Quote time Oct 20, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Corcept Therapeutics Incorporated (CORT)

Unavailable

Quotes may be delayed

$12.59B

Market Cap

549,192

Volume

228.1

P/E Ratio

Unavailable

Div Yield

Corcept Therapeutics Incorporated Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

23 Sep 2026

Corcept Therapeutics Incorporated reported A director or senior management change or compensation event

Corcept Therapeutics Incorporated filed an 8-K covering a director or senior management change or compensation event, Regulation FD disclosure, supporting financial statements or exhibits.

14 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Corcept Therapeutics Incorporated.

30 Jul 2026

Corcept Therapeutics Incorporated filed Form 10-Q

Corcept Therapeutics Incorporated submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

30 Jul 2026

Corcept Therapeutics Incorporated reported Operating or financial results

Corcept Therapeutics Incorporated filed an 8-K covering operating or financial results, Regulation FD disclosure, supporting financial statements or exhibits.

18 Jun 2026

Corcept Therapeutics Incorporated reported Another company event

Corcept Therapeutics Incorporated filed an 8-K covering another company event, supporting financial statements or exhibits.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$111.04M

Total assets (USD)$888.70M

Total liabilities (USD)$182.93M

Shareholders' equity (USD)$705.78M

Long-term debt (USD)$0

Debt due within a year (USD)$0

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$256.15M	$41.30M	$42.99M	$0.36	10-Q · 29 Jul 2026
Q1 2026	$164.90M	−$49.60M	−$31.76M	−$0.30	10-Q · 30 Apr 2026
Q4 2025	$202.13M	$4.49M	$24.29M	Unavailable	10-K · 24 Feb 2026
Q3 2025	$207.64M	$10.22M	$19.67M	$0.16	10-Q · 4 Nov 2025
Q2 2025	$194.43M	$26.68M	$35.15M	$0.29	10-Q · 31 Jul 2025
Q1 2025	$157.21M	$3.42M	$20.55M	$0.17	10-Q · 5 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $141.00

21.1% upside potential

📈

Strong Buy

Unavailable

👍

Buy

4

⏸️

Hold

0

📉

Sell

1

5 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 20 Oct 2026, 23:49 UTC Targets range 50.00–165.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

15

Oct 2026

WILSON JAMES N

Director

Open-market sale

$114.81 per share

10,000 shares

2

Oct 2026

Vieira Roberto Wandenkolk

President, Oncology

Option exercise

$21.63 per share

8,333 shares

2

Oct 2026

Vieira Roberto Wandenkolk

President, Oncology

Open-market sale

$116.10 per share

8,333 shares

2

Oct 2026

Lyon Joseph Douglas

See Remarks

Option exercise

$17.18 per share

9,190 shares

2

Oct 2026

Lyon Joseph Douglas

See Remarks

Open-market sale

$116.13 per share

9,190 shares

2

Oct 2026

Maduck Sean

See Remarks

Option exercise

$8.27 per share

24,587 shares

2

Oct 2026

Maduck Sean

See Remarks

Open-market sale

$116.28 per share

24,587 shares

1

Oct 2026

Lyon Joseph Douglas

See Remarks

Option exercise

$13.56 per share

810 shares

1

Oct 2026

Lyon Joseph Douglas

See Remarks

Open-market sale

$115.40 per share

810 shares

1

Oct 2026

Maduck Sean

See Remarks

Option exercise

$8.27 per share

413 shares

Top Shareholders

Blackrock, Inc.

12,432,023 shares

2.31% change

6/30/2026

Vanguard Group Inc

9,494,822 shares

-0.443% change

12/31/2025

Ingalls & Snyder Llc

7,934,507 shares

4.282% change

6/30/2026

Renaissance Technologies Llc

5,261,628 shares

-7.411% change

6/30/2026

Vanguard Portfolio Management Llc

5,044,638 shares

4.648% change

6/30/2026

Vanguard Capital Management Llc

4,172,482 shares

2.337% change

6/30/2026

Parallel Advisors, Llc

3,962,177 shares

-0.383% change

6/30/2026

Fmr Llc

3,337,618 shares

4.621% change

6/30/2026

State Street Corp

3,279,381 shares

2.45% change

6/30/2026

Aqr Capital Management Llc

2,582,561 shares

535.778% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 20 Oct 2026, 23:49 UTC· 1 day ago

Research coverage and investment tools

Corcept Therapeutics Incorporated (CORT) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$116.45 on 20 Oct 2026. That is 90% of the way from its 52-week low of US$28.66 to its 52-week high of US$126.38. Its market capitalisation was US$12.59 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$256.15M	$41.30M	$42.99M	$0.36	—	16.1%	$31.02M	10-Q · 29 Jul 2026 (opens in a new tab)
Q1 2026	$164.90M	−$49.60M	−$31.76M	−$0.30	—	-30.1%	−$16.97M	10-Q · 30 Apr 2026 (opens in a new tab)
Q4 2025	$202.13M	$4.49M	$24.29M	Unavailable	—	2.2%	$38.40M	10-K · 24 Feb 2026 (opens in a new tab)
Q3 2025	$207.64M	$10.22M	$19.67M	$0.16	—	4.9%	$54.48M	10-Q · 4 Nov 2025 (opens in a new tab)
Q2 2025	$194.43M	$26.68M	$35.15M	$0.29	—	13.7%	$44.24M	10-Q · 31 Jul 2025 (opens in a new tab)
Q1 2025	$157.21M	$3.42M	$20.55M	$0.17	—	2.2%	$4.67M	10-Q · 5 May 2025 (opens in a new tab)

Cash and equivalents: $111.04M
Total assets: $888.70M
Total liabilities: $182.93M
Shareholders' equity: $705.78M
Long-term debt: $0
Debt due within a year: $0

8-K · 23 Sep 2026 · Management change

Corcept Therapeutics Incorporated reported A director or senior management change or compensation event (opens in a new tab)

Corcept Therapeutics Incorporated filed an 8-K covering a director or senior management change or compensation event, Regulation FD disclosure, supporting financial statements or exhibits.
SCHEDULE 13G/A · 14 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Corcept Therapeutics Incorporated.
10-Q · 30 Jul 2026

Corcept Therapeutics Incorporated filed Form 10-Q (opens in a new tab)

Corcept Therapeutics Incorporated submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 30 Jul 2026

Corcept Therapeutics Incorporated reported Operating or financial results (opens in a new tab)

Corcept Therapeutics Incorporated filed an 8-K covering operating or financial results, Regulation FD disclosure, supporting financial statements or exhibits.
8-K · 18 Jun 2026

Corcept Therapeutics Incorporated reported Another company event (opens in a new tab)

Corcept Therapeutics Incorporated filed an 8-K covering another company event, supporting financial statements or exhibits.

Insider	Date	Transaction	Shares	Average price	Filing
WILSON JAMES N Director	15 Oct 2026	Open-market sale (S)	−10,000	$114.81	Form 4 (opens in a new tab)
Vieira Roberto Wandenkolk President, Oncology	2 Oct 2026	Option exercise (M)	+8,333	$21.63	Form 4 (opens in a new tab)
Vieira Roberto Wandenkolk President, Oncology	2 Oct 2026	Open-market sale (S)	−8,333	$116.10	Form 4 (opens in a new tab)
Lyon Joseph Douglas See Remarks	2 Oct 2026	Option exercise (M)	+9,190	$17.18	Form 4 (opens in a new tab)
Lyon Joseph Douglas See Remarks	2 Oct 2026	Open-market sale (S)	−9,190	$116.13	Form 4 (opens in a new tab)
Maduck Sean See Remarks	2 Oct 2026	Option exercise (M)	+24,587	$8.27	Form 4 (opens in a new tab)
Maduck Sean See Remarks	2 Oct 2026	Open-market sale (S)	−24,587	$116.28	Form 4 (opens in a new tab)
Lyon Joseph Douglas See Remarks	1 Oct 2026	Option exercise (M)	+810	$13.56	Form 4 (opens in a new tab)
Lyon Joseph Douglas See Remarks	1 Oct 2026	Open-market sale (S)	−810	$115.40	Form 4 (opens in a new tab)
Maduck Sean See Remarks	1 Oct 2026	Option exercise (M)	+413	$8.27	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Blackrock, Inc.	6/30/2026	12,432,023	2.31%
Vanguard Group Inc	12/31/2025	9,494,822	-0.443%
Ingalls & Snyder Llc	6/30/2026	7,934,507	4.282%
Renaissance Technologies Llc	6/30/2026	5,261,628	-7.411%
Vanguard Portfolio Management Llc	6/30/2026	5,044,638	4.648%
Vanguard Capital Management Llc	6/30/2026	4,172,482	2.337%
Parallel Advisors, Llc	6/30/2026	3,962,177	-0.383%
Fmr Llc	6/30/2026	3,337,618	4.621%
State Street Corp	6/30/2026	3,279,381	2.45%
Aqr Capital Management Llc	6/30/2026	2,582,561	535.778%

Previous close: 112.10 USD
Day range: 111.96 – 117.12 USD
52-week range: 28.66 – 126.38 USD
Volume: 549,192
Market cap: $12.59B
Average volume: 1,132,981
P/E ratio: 228.1
EPS (FY 2025, diluted): 0.82 USD
Shares outstanding: 108.10M
Beta (5Y monthly): 0.50

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 20:00 UTC· 1 day ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:32 UTC· 1 hour ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for CORT yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.